Letter: Methods of Preventing Contrast Nephropathy in Percutaneous Coronary Interventions

Abstract

Get full access to this article

View all access options for this article.

References

, et al. Spironolactone for preventing contrast-induced nephropathy after percutaneous coronary intervention in patients with acute myocardial infarction and chronic kidney Disease. Angiology. 2025;76(10):969-980.

Rundback

Nahl

Yoo

. Contrast-induced nephropathy. J Vasc Surg. 2011;54:575.

Bader

Berger

Heede

, et al.

What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?

Clin Nephrol. 2004;62:1-7.

Chandiramani

Cao

Nicolas

Mehran

. Contrast-induced acute kidney injury. Cardiovasc Interv Ther. 2020;35:209.

Windecker

Kolh

Alfonso

, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European society of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS)developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. 2014;35:2541.

Tsai

Patel

Chang

, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. JACC Cardiovasc Interv. 2014;7:1-9.

Aspelin

Aubry

Fransson

Strasser

Willenbrock

Berg

. Nephrotoxicity in high-risk patients study of I-O and low-osmolar non-ionic contrast media study I. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491.

Solomon

. Contrast media: are there differences in nephrotoxicity among contrast media? BioMed Res Int. 2014;2014:934947.